An increasing body of subsequent research has challenged the usefulness of the healthcare-associated pneumonia label, including studies that have cast doubt on links between multidrug-resistant pathogens and increased mortality.
A multidisciplinary panel of experts put together by the American Thoracic Society and Infectious Diseases Society of America released updated recommendations for the management of adults with community-acquired pneumonia.
A shift toward personalized medicine in pneumonia management would involve refining the diagnostic categories to include viral pneumonia, bacterial pneumonia, and noninfectious respiratory disease.
Pfizer announced topline data from one of its phase 3 studies for 20vPnC for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in adults.
The FDA has accepted for review a supplemental New Drug Application for Recarbrio™, to treat adult patients with hospital-acquired and ventilator-associated bacterial pneumonia.
